Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials-Reference-Cited by-同舟云学术

Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

Published:2019-07 Issue:7 Volume:19 Page:447-461
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Mushtaq Adeela,Iftikhar Ahmad,Hassan Hamza,Lakhani Midhat,Sagar FNU,Kamal Ahmad,Zahid Umar,Ali Zeeshan,Razzaq Faryal,Zar Muhammad Abu,Hassan Syeda Fatima,Safdar Ahmad,Raychaudhuri Sreejata,Anwer Faiz

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference48 articles.

1. Multiple myeloma epidemiology and survival: a unique malignancy;Kazandjian;Semin Oncol,2016

2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a Multicenter International Myeloma Working Group study;Kumar;Leukemia,2012

3. Practical approaches to the management of dual refractory multiple myeloma;Lee;Curr Hematol Malig Rep,2016

4. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial;Miguel;Lancet Oncol,2013

5. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma;Rychak;Br J Haematol,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of targeted protein degradation to treat and study cancer;The Journal of Pathology;2024-06-17

2. Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China;Cancer Medicine;2024-05

3. Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis;Expert Review of Hematology;2024-03-05

4. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma;Anti-Cancer Drugs;2023-04-06

5. Pomalidomide-induced lung injury: A case report;Medicine;2023-01-13